Cormedix Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
82
- Stock Symbol
-
CRMD
- Share Price
-
$13.60
- (As of Friday Closing)
Cormedix General Information
Description
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Contact Information
Website
www.cormedix.comCorporate Office
- 300 Connell Drive
- Suite 4200
- Berkeley Heights, NJ 08807
- United States
Corporate Office
- 300 Connell Drive
- Suite 4200
- Berkeley Heights, NJ 08807
- United States
Cormedix Stock Performance
As of 20-Jun-2025, Cormedix’s stock price is $13.60. Its current market cap is $923M with 67.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.60 | $13.58 | $3.61 - $15.38 | $923M | 67.8M | 2.05M | $0.24 |
Cormedix Financials Summary
As of 31-Mar-2025, Cormedix has a trailing 12-month revenue of $82.6M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 350,349 | 446,012 | 120,209 | 116,044 |
| Revenue | 82,554 | 43,472 | 0 | 65 |
| EBITDA | 15,378 | (21,557) | (48,916) | (30,502) |
| Net Income | 17,180 | (17,930) | (46,339) | (29,702) |
| Total Assets | 149,583 | 118,846 | 82,060 | 62,038 |
| Total Debt | 477 | 517 | 668 | 802 |
Cormedix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cormedix Comparisons
Industry
Financing
Details
Cormedix Competitors (40)
One of Cormedix’s 40 competitors is AstraZeneca, a Formerly PE-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AstraZeneca | Formerly PE-Backed | Cambridge, United Kingdom | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Amneal Pharmaceuticals | Formerly PE-Backed | Bridgewater, NJ | ||||
| China Resources Pharmaceutical Group | Corporation | Hong Kong, Hong Kong | ||||
| Astex Pharmaceuticals | Corporate Backed or Acquired | Cambridge, United Kingdom |
Cormedix Patents
Cormedix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11738120-B1 | Synthesis of taurolidine, purity profiles and polymorphs | Active | 14-Apr-2022 | ||
| EP-4507746-A1 | Improved synthesis of taurolidine, purity profiles and polymorphs | Pending | 14-Apr-2022 | ||
| AU-2019331913-A1 | Taurolidine treatment for myc-expressing tumors in mammalian bodies | Pending | 31-Aug-2018 | ||
| CA-3111100-A1 | Taurolidine treatment for myc-expressing tumors in mammalian bodies | Pending | 31-Aug-2018 | ||
| EP-3843747-A4 | Taurolidine treatment for myc-expressing tumors in mammalian bodies | Pending | 31-Aug-2018 | A61K45/06 |
Cormedix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cormedix ESG
Risk Overview
Risk Rating
Updated April, 16, 2025
40.24 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Cormedix FAQs
-
When was Cormedix founded?
Cormedix was founded in 2006.
-
Where is Cormedix headquartered?
Cormedix is headquartered in Berkeley Heights, NJ.
-
What is the size of Cormedix?
Cormedix has 82 total employees.
-
What industry is Cormedix in?
Cormedix’s primary industry is Pharmaceuticals.
-
Is Cormedix a private or public company?
Cormedix is a Public company.
-
What is Cormedix’s stock symbol?
The ticker symbol for Cormedix is CRMD.
-
What is the current stock price of Cormedix?
As of 20-Jun-2025 the stock price of Cormedix is $13.60.
-
What is the current market cap of Cormedix?
The current market capitalization of Cormedix is $923M.
-
What is Cormedix’s current revenue?
The trailing twelve month revenue for Cormedix is $82.6M.
-
Who are Cormedix’s competitors?
AstraZeneca, Novartis, Amneal Pharmaceuticals, China Resources Pharmaceutical Group, and Astex Pharmaceuticals are some of the 40 competitors of Cormedix.
-
What is Cormedix’s annual earnings per share (EPS)?
Cormedix’s EPS for 12 months was $0.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
